Clinical Trials Logo

Filter by:
NCT ID: NCT05568095 Active, not recruiting - Clinical trials for Advanced Upper Gastrointestinal Tract Adenocarcinoma

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

STAR-221
Start date: November 21, 2022
Phase: Phase 3
Study type: Interventional

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti PD-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

NCT ID: NCT05549505 Active, not recruiting - Breast Cancer Clinical Trials

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Start date: February 15, 2023
Phase: Phase 2
Study type: Interventional

This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with ER+/HER2- localized breast cancer.

NCT ID: NCT05514548 Active, not recruiting - Clinical trials for Diabetic Kidney Disease

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Start date: October 19, 2022
Phase: Phase 2
Study type: Interventional

The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus

NCT ID: NCT05469867 Active, not recruiting - Glaucoma Eye Clinical Trials

Pivotal Trial for a Synthetic Tissue Substitute for Concealment of Artificial Ocular Implants

EverPatch
Start date: August 16, 2022
Phase: N/A
Study type: Interventional

This clinical trial will assess the clinical safety and performance of the CorNeat EverPatch device used as a tissue substitute for concealment of artificial ocular implants.

NCT ID: NCT05456685 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Start date: September 28, 2022
Phase: Phase 2
Study type: Interventional

IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy.

NCT ID: NCT05440513 Active, not recruiting - Hypertension Clinical Trials

A Study of Non-Vascular Renal Denervation Using the Verve Medical Phoenix ™ System

TUSK
Start date: January 25, 2021
Phase: N/A
Study type: Interventional

The aim of the study is to assess the safety and effectiveness of a novel device for renal denervation to lower blood pressure in people with uncontrolled hypertension. Prior studies demonstrate the potential benefit of renal denervation in hypertension, though these studies primarily denervate the kidneys by passing catheters through the arteries in the groin into the renal arteries. The TUSK study utilizes the Phoenix system to perform denervation by advancing the device (a thin electrode) through the urinary tract into the kidneys where radiofrequency energy is briefly applied to denervate the kidneys.

NCT ID: NCT05425745 Active, not recruiting - Clinical trials for Hypercholesterolemia

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

BROOKLYN
Start date: July 25, 2022
Phase: Phase 3
Study type: Interventional

This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hypercholesterolemia (HeFH).

NCT ID: NCT05405660 Active, not recruiting - Clinical trials for Chronic Inducible Urticaria

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Start date: June 28, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Inducible Urticaria who remain symptomatic despite the use of H1-antihistamines.

NCT ID: NCT05403372 Active, not recruiting - Heart Failure Clinical Trials

Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure

EASE HF
Start date: May 7, 2022
Phase: N/A
Study type: Interventional

This is a prospective, single arm feasibility study to establish safety and performance of the PAS-C System in subjects with heart failure and elevated left atrial pressure.

NCT ID: NCT05395091 Active, not recruiting - Clinical trials for Osteoporosis, Postmenopausal

Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND

ALVOBOND
Start date: August 23, 2022
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, parallel design, repeat dose, 2 arm, multicenter study comparing the efficacy, safety, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of AVT03 and US-Prolia in postmenopausal women with osteoporosis.